BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 2316557)

  • 1. Gram-negative bacillary pneumonia in the nosocomial setting. Role of aztreonam therapy.
    Cook JL
    Am J Med; 1990 Mar; 88(3C):34S-37S; discussion 38S-42S. PubMed ID: 2316557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of aztreonam in lower respiratory tract infections.
    Cook JL
    Urology; 1988 Jun; 31(6 Suppl):33-6. PubMed ID: 3287748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia.
    Schentag JJ; Vari AJ; Winslade NE; Swanson DJ; Smith IL; Simons GW; Vigano A
    Am J Med; 1985 Feb; 78(2A):34-41. PubMed ID: 3881947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined aztreonam and gentamicin therapy for pseudomonal lower respiratory tract infections.
    Andrews R; Fasoli R; Scoggins WG; Algozzine GJ; Spann RW; Sundaresh KV; Mathers JA; Babb R; Kuppinger M; Cooper B
    Clin Ther; 1994; 16(2):236-52. PubMed ID: 8062319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of aztreonam in gram-negative pneumonia versus a therapeutic regimen that includes an aminoglycoside. Spanish Study Group.
    Marco V; Gobernado M; Santos M; Rabinad E
    Chemotherapy; 1989; 35 Suppl 1():81-8. PubMed ID: 2659295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of aztreonam in the treatment of nosocomial pneumonia in the critically ill surgical patient.
    Boucher BA
    Am J Surg; 2000 Feb; 179(2A Suppl):45S-50S. PubMed ID: 10802265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients.
    Rabinad E; Bosch-Perez A
    Chemotherapy; 1989; 35 Suppl 1():1-7. PubMed ID: 2659288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aztreonam therapy for serious gram-negative bacillary infections.
    Cone LA; Woodard DR
    Rev Infect Dis; 1985; 7 Suppl 4():S794-802. PubMed ID: 3909339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with aztreonam.
    Stutman HR
    Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S109-12; discussion S128-32. PubMed ID: 2682508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aztreonam.
    Tunkel AR; Scheld WM
    Infect Control Hosp Epidemiol; 1990 Sep; 11(9):486-94. PubMed ID: 2230052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aztreonam in the prevention and treatment of infection in neutropenic cancer patients.
    Rolston KV; Bodey GP; Elting L
    Am J Med; 1990 Mar; 88(3C):24S-29S; discussion 38S-42S. PubMed ID: 2180294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aztreonam treatment of severe infections caused by gram-negative aerobic bacilli].
    Peter JD; Jehl F; Froehly S; Dupeyron JP; Monteil H; Rosset MA
    Pathol Biol (Paris); 1988 May; 36(5):525-30. PubMed ID: 3043352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
    Scully BE; Neu HC
    Am J Med; 1985 Feb; 78(2):251-61. PubMed ID: 4038574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections.
    Bjornson HS; Ramirez-Ronda C; Saavedra S; Rivera-Vázquez CR; Liu C; Hinthorn DR
    Clin Ther; 1993; 15(1):65-78. PubMed ID: 8458056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative analysis of aztreonam + clindamycin versus tobramycin + clindamycin or amikacin + mezlocillin in the treatment of gram-negative lower respiratory tract infections.
    Rivera-Vazquez CR; Ramirez-Ronda CH; Rodriguez JR; Saavedra S
    Chemotherapy; 1989; 35 Suppl 1():89-100. PubMed ID: 2659296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Brogden RN; Heel RC
    Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the in vitro activity of aztreonam on 1990 gram-negative bacterial strains recently isolated in Campania hospitals].
    Covelli I; Bolletti-Censi M; Fortunato A; Guarino A; Spagnoletti G; Amato G; Nani E; Anzivino D; Lavitola A; Gulletta E
    Boll Ist Sieroter Milan; 1986; 65(1):22-31. PubMed ID: 3521671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical efficacy of aztreonam in refractory infections in children].
    Ogura H; Hamada F; Fujieda M; Matsumoto K; Araki K; Ogura Y; Kuramitsu M; Kurashige T; Kitamura I
    Jpn J Antibiot; 1985 Nov; 38(11):3349-57. PubMed ID: 4094068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aztreonam in the therapy of severe gram-negative infections.
    Davies A; Stone J; Hassan A; Quarty P; Green T
    Chemioterapia; 1987 Jun; 6(2 Suppl):389-90. PubMed ID: 3509455
    [No Abstract]   [Full Text] [Related]  

  • 20. Aminoglycosides, imipenem, and aztreonam.
    Johnson JG; Hardin TC
    Clin Podiatr Med Surg; 1992 Apr; 9(2):443-64. PubMed ID: 1586911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.